CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Portable X-ray vision is one step closer to reality with OXOS Medical

From TechCrunch

By Haje Jan Kamps

April 5, 2023

Portable X-ray vision is one step closer to reality with OXOS Medical

The global medical imaging market was valued at a touch over $28 billion in 2021, and is only expected to rise with an increase in demand for early-detection services as well as lifestyle and age-related conditions. Yet at the same time as demand for radiology services is increasing, the number of available radiographers is decreasing. In the U.S., almost half of radiographers are approaching retirement age and there are fewer residents lining up to fill their soon-to-be vacancies. The situation in the U.K. is similarly critical, with a shortfall of 1,670 radiologists reported in the 2021 Royal College of Radiologists census, and no improvement in sight. It’s an area that’s not just ripe for improvement, but where the problem is urgent. It’s against that backdrop that OXOS Medical just raised $23 million in Series A funding with the intention of delivering a “radiology department in a box.”

“X-ray is the primary medical imaging modality, used at the beginning or end of over 70% of health interventions, but 80% of the world lacks access to imaging,” explains OXOS’ CEO and co-founder, Evan Ruff. Clearly, a lack of supply has the potential to negatively impact healthcare provision for millions of people, and OXOS believes it can help to alleviate that. “We aim to put safe, powerful and simple X-ray technology in the hands of urgent care centers, sports teams, home care and international mission operations, where a real-time diagnosis is critical to saving human lives.”

This $23 million Series A funding was from Parkway Venture Capital and Intel Capital, and brings OXOS Medical’s total funding to $45 million. It also saw Gregg Hill, Parkway Venture Capital co-founder and managing partner, and Eric King, Intel Capital investment director, join the OXOS board of directors to help accelerate the company’s growth. Ruff explained how this funding will be used to help scale up OXOS, as well as push on with its technological advantages.

Nanox, maker of a low-cost scanning service to replace X-rays, expands Series B to $51M

“This fundraise was all about setting OXOS up for scale,” says Ruff. “As a small company, there are certain things that we just can’t do. This money unlocks a number of new initiatives, everything from cost reduction activities, to product development, to advanced research, and other initiatives. Our goal is for anyone, anywhere, to be able to unpack an OXOS device and have a complete radiography solution available immediately.”

While OXOS is keen to continue to supply devices in traditional markets, it also recognizes that its technology is suited for use in a wide variety of medical and non-medical settings.

“OXOS devices use 80% less radiation than existing devices, shifting the envelope of what’s possible in radiography,” says Ruff. “OXOS’ smart and safe technology addresses the growing needs of orthopedic and radiographic professionals across all care scenarios, expanding access well beyond established sectors. We’re seeing massive pull into urgent care, professional sports and family practices, as well as other non-medical applications.”

OXOS claims that its devices are the only ones on the market that can provide both static images (digital radiography) and live imaging (dynamic digital radiography), for both diagnostic and surgical radiography, in any setting. Together with their low radiation profiles, and the ability to provide imaging from a small form factor, which is viewable by medical practitioners anywhere on any device via the OXOS Cloud Platform, OXOS believes it can make X-rays more accessible.

If the short-term goals focus on scaling, volume and pushing into other sectors, what about the long-term future for OXOS?

“Every year, the U.S. spends over $50 billion on radiography. There is another $75 to $100 billion spent worldwide. OXOS technology provides a safe, point-and-click, end-to-end solution for every one of those use cases,” says Ruff, showing how big a market is available to it, and how it’s possible to make a positive impact on healthcare. “As our volumes increase and the number of deployed OXOS devices increases, the OXOS platform will be a huge resource for researchers and diagnostic innovators to build on, automating radiographic diagnostics and making healthcare cheaper.”

“As we execute on our goals, OXOS will grow into an independent, public company,” says Ruff.

Portable X-ray vision is one step closer to reality with OXOS Medical by Haje Jan Kamps originally published on TechCrunch

Most Recent

Startup Abby Care raises $82 million to turn family members into paid caregivers

As a kid, Havi Nguyen sometimes missed school to translate at doctor's appointments, and was managing Medicaid paperwork for her family, who had recently immigrated from Vietnam.

Oct 18, 2026

795 accounts funded by ADI Predictstreet's own fee-collecting wallet drove 99% of the FIFA-partnered prediction market's activity since late August

ADI Predictstreet, backed by Abu Dhabi's royal family, paid close to $150 million for advertising rights during the World Cup

Oct 18, 2026

China's CXMT sees shares drop over 6% as investors look past chipmaker's profit turnaround

CXMT shares fell over 6% on Monday after the company released its earnings forecast for the first nine months of 2026.

Oct 18, 2026

World launches World ID suite for banks, makes Zoom deepfake check generally available

The identity project co-founded by OpenAI CEO Sam Altman named Bain Capital and VanEck Funds among its design partners but did not name a bank that has started using the product.

Oct 18, 2026

Similar Posts

Scan.com, which gives patients direct access to private medical imaging services, raises $12M

Anyone in the U.K. who has tried to book an NHS medical appointment of late will know just how much of an ordeal it can be, with median waiting times for consultant-led elective care (i.e. pre-planned clinical treatment) currently sitting at around 14.6 weeks in England. This has led to a spike in people turning […]

Apr 16, 2023

Oxford spinout RADiCAIT uses AI to make diagnostic imaging more affordable and accessible — catch it at TechCrunch Disrupt 2025

“What we really do is we took the most constrained, complex, and costly medical imaging solution in radiology, and we supplanted it with what is the most accessible, simple and affordable, which is CT,” Sean Walsh, RADiCAIT’s CEO told TechCrunch.

Oct 27, 2025

Chinese medical device firm Mindray plans mln deal to control APT Medical

Mindray plans 6.65 billion yuan deal to gain control of APT Medical to expand in cardiovascular businesses.

Jan 28, 2024

Glass Health is building an AI for suggesting medical diagnoses

While a medical student at UC San Francisco, Dereck Paul grew concerned that innovation in medical software was lagging behind other sectors, like finance and aerospace. He came to believe that patients are best served when doctors are equipped with software that reflects the cutting edge of tech, and dreamed of starting a company that’d […]

Sep 8, 2023